Improved Iron Overload with Pegcetacoplan in Eculizumab-Experienced Patients with Paroxysmal Nocturnal Hemoglobinuria [PDF]
International Journal of Molecular SciencesComplement factor 5 (C5) inhibitors for paroxysmal nocturnal hemoglobinuria (PNH) may cause iron overload due to residual intravascular hemolysis (IVH) and emergent extravascular hemolysis (EVH).
Shammo J +4 more
exaly +3 more sources
Retinal vasculitis following intravitreal pegcetacoplan administration
American Journal of Ophthalmology Case ReportsPurpose: To describe a case of retinal vaso-occlusive vasculitis with associated lid edema and conjunctivitis following intravitreal pegcetacoplan administration in a patient with geographic atrophy (GA).
Stella Douros +2 more
doaj +2 more sources
Pegcetacoplan: A New Opportunity for Complement Inhibition in PNH
Journal of Blood Medicine, 2023 Ilene Ceil Weitz Jane Anne Nohl Division of Hematology, Keck-USC School of Medicine, Los Angeles, CA, USACorrespondence: Ilene Ceil Weitz, Jane Anne Nohl Division of Hematology, Keck-USC School of Medicine, Los Angeles, CA, USA, Tel +1-323-865-3950, Fax +
Weitz IC
doaj +1 more source
Complement-targeted therapies for C3 glomerulopathy and atypical hemolytic uremic syndrome: a time-limited rapid systematic review with narrative synthesis [PDF]
Frontiers in MedicineC3 glomerulopathy (C3G) and atypical hemolytic uremic syndrome (aHUS) are rare complement-mediated kidney diseases with differing injury sites and therapeutic targets. We conducted a time-limited rapid systematic review to synthesize clinical evidence on
Qishun Wu +4 more
doaj +2 more sources
Successful Treatment of Refractory Immune Complex-Mediated Membranoproliferative Glomerulonephritis with Pegcetacoplan: A Case Report [PDF]
Glomerular DiseasesImmune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN) lacks proven targeted therapy and is often refractory to nonspecific immunosuppression.
Abdullah Al-Muhaiteeb +2 more
doaj +2 more sources
Pharmacological Characterization of a Novel Complement C3 Inhibitor Antibody Fragment [PDF]
Ophthalmology and TherapyIntroduction The complement system is a key driver of geographic atrophy (GA), a disease that leads to progressive, irreversible vision loss. Pharmacological preclinical studies characterizing an antibody fragment, which is a novel complement C3 ...
Stephanie Jungmichel +8 more
doaj +2 more sources
Emerging Infectious DiseasesComplement C5 inhibitors bring an increased risk for Neisseria infections. A novel complement C3 inhibitor, pegcetacoplan, was recently approved to treat paroxysmal nocturnal hemoglobinuria, a condition commonly treated with complement C5 inhibitors. We
Leo Starck +8 more
doaj +2 more sources
Indirect treatment comparison of iptacopan versus pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and residual anemia despite C5 inhibitor treatment [PDF]
Journal of Comparative Effectiveness ResearchThis study conducted an indirect treatment comparison (ITC) of iptacopan, the first oral monotherapy targeting factor B, versus pegcetacoplan, a subcutaneous infusion targeting complement component 3, in patients with paroxysmal nocturnal ...
Austin Kulasekararaj +9 more
doaj +2 more sources
Guiding syringe selection for intravitreal injections: injectability and stability analysis of compounded pegcetacoplan (SYFOVRE) and the broader implications for high-viscosity ophthalmic therapies [PDF]
International Journal of Retina and VitreousPurpose SYFOVRE, the brand name of pegcetacoplan and the first FDA-approved treatment for geographic atrophy arising from dry age-related macular degeneration, is currently available only in vial format.
Tina Felfeli +2 more
doaj +2 more sources
HematologyObjectives A subset of paroxysmal nocturnal hemoglobinuria (PNH) patients develops clinically relevant extravascular hemolysis when treated with complement C5 inhibitors.
Wolfgang Füreder, Andreas Reinisch
doaj +2 more sources